Core Viewpoint - The ongoing power struggle within Sinovac Biotech has led to significant operational challenges, including a near delisting from NASDAQ, despite the company's previous financial success during the pandemic [2][4][6]. Group 1: Company Background and Current Status - Sinovac Biotech, once known as the "king of vaccines," has managed to retain its NASDAQ listing after receiving approval from the NASDAQ Hearing Committee [2]. - The company faced a delisting decision two months prior, which was a result of its inability to submit timely financial reports due to internal conflicts [4][5]. - Sinovac's stock has been suspended for nearly seven years due to ongoing disputes over control, preventing the company from releasing financial statements [6][8]. Group 2: Internal Power Struggle - The internal conflict began in 2016 with the privatization of Sinovac, leading to a split between co-founders Yin Weidong and Pan Aihua, who have since formed opposing factions [10][11]. - The struggle intensified during the 2018 shareholder meeting, where Yin's board was opposed by Pan's faction, resulting in legal battles that have continued for years [10][12]. - A ruling from the UK Privy Council in January 2025 confirmed procedural flaws in the 2018 shareholder meeting, further complicating the internal governance [12][13]. Group 3: Financial Performance and Challenges - In 2021, Sinovac reported revenues of approximately RMB 128 billion and a net profit exceeding RMB 95.5 billion, largely due to the demand for COVID-19 vaccines [22]. - However, post-pandemic, the company's performance has declined sharply, with a projected revenue drop of 23.04% in 2024 and a net profit decrease of 66.36% [25]. - The company is also facing a significant cash outflow due to a proposed dividend plan totaling $7.448 billion (approximately RMB 53.8 billion), which could deplete its cash reserves and hinder future R&D efforts [26][27]. Group 4: Future Outlook - To avoid delisting, Sinovac must submit its 2024 annual report and 2025 interim report by May 11, 2025, which requires a legally recognized board to approve the financial statements [17][18]. - The ongoing internal conflict poses a risk to the company's governance and operational stability, making it imperative for Sinovac to establish a legitimate board to facilitate decision-making and strategic growth [28][29].

Core Viewpoint - The article emphasizes the importance of awareness and preventive measures against viral hepatitis, highlighting that it is preventable and treatable, and calls for collective action to eliminate its harm [1][2]. Group 1: Understanding Hepatitis - The liver is referred to as the body's largest "chemical factory," responsible for synthesis, metabolism, detoxification, and defense [1]. - Hepatitis is categorized into viral and non-viral types, with viral hepatitis being infectious and having specific transmission routes, including hepatitis A, B, C, D, and E [1]. - Non-viral hepatitis includes alcoholic hepatitis, fatty liver, autoimmune liver disease, and genetic metabolic diseases [1]. Group 2: Prevention and Treatment - Vaccination, blocking transmission routes, and adopting healthy lifestyle habits are effective preventive measures against viral hepatitis [2]. - Vaccines can effectively prevent infections of hepatitis A, B, and E, while hepatitis C can often be treated and cleared with short-term antiviral therapy [2]. - Early detection is crucial as many viral hepatitis infections lack specific symptoms in the early stages; recommended screening includes liver function tests and hepatitis virus quantification [2].

Core Viewpoint - The vaccine industry is expected to see a recovery in sales growth trends for key vaccine varieties in 2025, driven by a low base effect, which will improve company performance [1] Industry Summary - In Q1 2025, the overall number of vaccine batch approvals was 697, representing a year-on-year decline of 14% [1] - Significant year-on-year growth was observed in flu vaccines, DTP vaccines, and hepatitis vaccines, while polio vaccines, shingles vaccines, rotavirus vaccines, and HPV vaccines experienced notable declines [1] - The development of therapeutic vaccines for cancer is emerging as a hot area for vaccine indication expansion, with domestic research still in its early stages [1] - The competitive landscape for traditional key vaccine pipelines is intensifying, with many domestic companies entering the market [1] Company Summary - It is anticipated that key vaccine varieties will recover in sales growth in 2025, which will positively impact company performance [1] - Continuous advancement in innovative vaccine pipelines is expected to provide companies with greater market opportunities and potential for international expansion in the future [1]